The overall project consists of six functional work streams. Three are central representing the core scientific work and can be directly mapped onto the main objectives described in the previous section. Another three are instrumental pieces supporting the core scientific work. Although the six functional work streams are described separately below, to achieve the project’s goals, close collaboration and cross-cutting actions between them are crucial.
The purpose is to provide scientific oversight and management support to the project, ensuring adequate dovetailing with EPAD.
This part of the work is devoted to all technical and logistic operations needed to support the correct development of the AMYPAD project.
To deals with the tracer production and distribution, scan acquisition, QC, transfer, quantification and, ultimately, sharing of image data across the 3 main aims of the study.
The diagnostic study will determine, in a real-life clinical setting, for whom diagnostic Aß imaging is appropriate, when this is best performed and how the resulting information is influencing diagnostic thinking, patient management and ultimately decision trees and cost-effectiveness of dementia care.
AMYPAD selects and follows up a memory clinic population investigated for memory complaints or possible AD. Patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and dementia possibly due to AD but with unclear aetiology are studied to estimate the impact of β-amyloid imaging on change of diagnosis, diagnostic confidence, treatment decisions, and management changes.
This work stream in AMYPAD is ultimately tasked with ensuring efficiencies in delivering the interaction with the EPAD Programme and other deep phenotyped European cohorts of cognitively unimpaired participants (ECCU). PET-Amyloid imaging up to 2000 subjects enrolled in the EPAD LCS or other non EPAD cohorts are undertaken. A sub-population of these subjects will have a repeat PET Amyloid scan conducted 1-2 years later. The PET-Amyloid imaging represents an additional important biomarker amongst a multitude of cognitive, imaging and CSF biomarkers already performed in the EPAD LCS and in the remaining ECCUs.
To focus on understanding natural history of AD, defining the window for intervention and trial-readiness population in conjunction with EPAD Longitudinal Cohort Study and other similar European Cohorts.
This unit is focusing on the full quantitative data generated in AMYPAD to go beyond the analyses planned in the diagnostic and prognostic studies that both focus on global amyloid status as a dichotomous measure.
The ultimate goal is to establish predictors of decline by using quantitative baseline and longitudinal PET measurements and determine how this can be best used to plan and monitor treatment.
This team is leading and coordinating external dissemination activities (including publication and dissemination strategy), addressing liaison with external stakeholders, including regulators and patients, and examining ethical issues and data access policies.